Disulfiram for Cocaine Abuse in Buprenorphine Treatment

Sponsor

Yale University (Other)

Overall Status

Completed

CT.gov ID

NCT00913484

Collaborator

National Institute on Drug Abuse (NIDA) (NIH)

177

Enrollment

Locations

Arms

Duration (Months)

88.5

Patients Per Site

2.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The investigators are proposing a placebo-controlled clinical trial to evaluate the efficacy and potential mechanisms of action of disulfiram (versus placebo) for treating cocaine abuse in subjects with concurrent opiate dependence and cocaine abuse or dependence maintained on buprenorphine/naloxone combination.

Condition or Disease	Intervention/Treatment	Phase
Cocaine Dependence Opioid Dependency	Drug: Disulfiram Drug: Placebo	Phase 2

Detailed Description

The Specific Aims and hypotheses for the proposed study are as follows:

To compare the efficacy of disulfiram versus placebo for the treatment of buprenorphine maintained patients with concurrent opioid and cocaine dependence. Study hypothesis 1 is that disulfiram is superior to placebo.
To evaluate whether dopamine-B-hydroxylase (DBH) genotypes associated with high, intermediate or low enzyme activity predict responses to disulfiram treatment of cocaine use in buprenorphine treated subjects. Study hypothesis 2 is that disulfiram efficacy is higher in subjects with low DBH compared to subjects with high DBH.
To explore whether baseline measures of alcohol use predict response to disulfiram. Study Hypothesis 3 is that the effects of disulfiram on cocaine use are independent of the severity of baseline alcohol use.

Study Design

Study Type:

Interventional

Actual Enrollment :

177 participants

Allocation:

Randomized

Intervention Model:

Factorial Assignment

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

Disulfiram for Cocaine Abuse in Buprenorphine Treatment

Study Start Date :

Oct 1, 2000

Actual Primary Completion Date :

Feb 1, 2004

Actual Study Completion Date :

Feb 1, 2004

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Disulfiram Disulfiram 250 mg per day	Drug: Disulfiram Disulfiram 250 mg per day
Placebo Comparator: Placebo Placebo	Drug: Placebo Placebo daily

Arm

Intervention/Treatment

Experimental: Disulfiram

Disulfiram 250 mg per day

Drug: Disulfiram

Disulfiram 250 mg per day

Placebo Comparator: Placebo

Placebo

Drug: Placebo

Placebo daily

Outcome Measures

Primary Outcome Measures

Cocaine abstinence [12 weeks]

Secondary Outcome Measures

Opioid abstinence [12 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 45 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

English speaking adults ages 18 - 45.
Meeting FDA criteria for agonist maintenance treatment and DSM-IV criteria for opioid dependence and cocaine dependence or abuse as assessed by SCID interview and documented by opioid positive and cocaine positive urine toxicology testing.
Women of childbearing age will be included provided they agree to adequate contraception and to monthly pregnancy testing during the course of the study.

Exclusion Criteria:

Current physiologic dependence on benzodiazepines or alcohol, unless first detoxified. Subjects who use/abuse alcohol will be included but will be cautioned about alcohol use during the study because of the possibility of an alcohol-disulfiram reaction.
Use of the antibiotic agents metronidazole or clotrimazole, which have disulfiram-like effects in combination with alcohol.
Presence of significant cardiovascular, renal, hepatic or neurologic illness. Subjects with markedly abnormal liver function tests (i.e., AST of ALT > 3X normal) will also be excluded.
Presence of any of the following cardiovascular risk factors:
age > 45 years
history of cocaine-related chest pain
systolic blood pressure > 140 or diastolic blood pressure > 90
evidence of ischemia or past myocardial infarction on EKG
significant family history of risk (first degree relative with myocardial infarction prior to age 60)
elevated cholesterol (> 300 mg/dl), elevated LDL (> 170 mg/dl) or low HDL (< 20 mg/dl)
Maintenance on methadone at doses greater than 30mg daily. Admittance to the study will only be offered to individuals who have been maintained on 30 mg of methadone or less daily for seven days prior to entering the study.
Current suicide or homicide risk or current psychotic disorder.
Inability to read or understand the symptom checklists.